Comments
Drug firm Granules India on Monday said it has received marketing nod from Health Canada for its Acetaminophen extended-release tablets used in the treatment of arthritis pain.
Approval within 8 months
The company has received approval from Health Canada for Acetaminophen extended-release tablets OTC, 650 mg, Granules India said in a regulatory filing.
“We received the approval within eight months of filing. This is a step towards global expansion of our core molecules. The approval of Acetaminophen extended-release tablets OTC, 650mg..., is a good addition to our portfolio,” Granules USA, Inc & Granules Pharmaceuticals, Inc Executive Director, Priyanka Chigurupati said.
The company will be launching the product in Canadian market soon, she added.
The drug will be manufactured at the company’s manufacturing facility located in Gagillapur, Hyderabad, the filing said.
Shares of Granules India were trading at ₹335.90 per scrip on BSE, up 1.53 per cent from its previous close.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.